In 2009, revenues for the Swiss biotechnology industry grew 7.3% to CHF 9,343 million ($8,572 million). R&D spending by the industry rose 6.2% to CHF 2,199 million. Publicly held firms accounted for 80% of revenues and 72% of R&D spending. However, profits for the industry fell 47.6% to CHF 100 million, and liquidity fell 5.3% to CHF 2,379 million. In total, Swiss biotech firms raised CHF 370 million in financing last year, a 62% increase, led by Novimmune, which raised CHF 60 million. Private companies received 87% of capital investments. The Swiss biotech industry consists of 162 companies that are developing biotech drugs and 65 companies that supply products to the industry. The number of industry employees grew 6.0% in 2009 to 19,071, 63% of whom were employed by public entities.

Source: Swiss Biotech Association